The firm said it expects that Noridian will similarly confirm its draft local coverage determination, bringing coverage for Percepta to around 35 million.
The investment bank noted Veracyte's "disciplined" approach to developing and commercializing tests, and said the company stands out in its sector.
Tests sold by Veracyte, CareDx, Biodesix, Genomic Health, BioTheranostics, and fetal aneuploidy trisomy risk testing will see improved rates from earlier proposals.
The investment bank said Veracyte's negative classifier tests are of significant value to healthcare providers and payors.
The revenue increase was driven by increased sales of its Afirma gene classifier thyroid test, as well as improved predictability of payments.
The company said it would use the net proceeds from the offering for working capital, and possibly to acquire or invest in other companies or technologies.
The company said that the anticipated revenue growth reflects higher sales and gains made with payers for its Afirma gene expression classifier thyroid test.
The draft LCD comes one week after Noridian issued its own draft determination on the test.
A recent draft local coverage determination from Medicare contractor Noridian is one step along a growth path, according to Veracyte's CEO.
The firm expects the final LCD will go into effect around the beginning of next year, and that three remaining Medicare contractors will soon post draft LCDs for its test.
Holden Thorp is to be the new editor-in-chief of Science and its related journals.
A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.
Adelaide University has suspended the head of an ancient DNA lab as its investigation of workplace bullying continues, Australia's ABC News reports.
In PNAS this week: gene expression profiles of adipocyte subtypes, computational approach for improving plant expressome analysis, and more.